Oncology

Merck Serono Oncology is focused on developing novel cancer-specific therapies that provide beneficial therapeutic outcomes and create new options for cancer patients.

Key to Merck Serono’s success in oncology is the research and development of agents that not only have a combined approach when it comes to targeting tumour cells, the tumour microenvironment, and the innate and adaptive immune system.

Combination is key for Merck Serono not only in developing products that target multiple aspects of the disease process and are suitable for use in combination with established standard therapies, but also for:

Combining innovative thinking with intelligent research and technical excellence
Merck Serono Oncology has brought together a dedicated group of individuals who can look beyond conventional horizons to explore further possibilities. They have the experience and motivation we need to identify potential therapeutic targets and develop novel cancer treatment strategies.

Combining insights, experience and skills
Merck Serono is committed to working in partnership with oncology experts, patients and healthcare providers. We strive to meet the needs of patients for better medicines, and to improve access to these medicines by collaborative teamwork and sharing of skills. Moreover, this strategy combines the efficacy of radiotherapy, surgery and medical treatments to create a multidisciplinary approach for the benefit of cancer patients everywhere.

Merck Serono Oncology combines approaches that target the tumour cell, the tumour environment and the immune system to optimise therapeutic success.

Targeting the tumour cell
The elimination of the tumour cell remains the essential goal for cancer therapies. Given that there are a variety of ways to achieve this goal, Merck Serono’s oncology pipeline includes therapies with a wide range of expected actions against tumour cells, especially interference with proliferation and survival pathways, offering efficacy against many different tumour types.